SciClone Pharmaceuticals to Report Fourth Quarter and Year-End Results for 2010 on March 16

FOSTER CITY, CA, Feb 28 (MARKET WIRE) --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
plans to report fourth quarter and year-end results for 2010 on
Wednesday, March 16, 2011. SciClone will host a conference call to give a
business update and guidance for 2011 at 4:30 pm ET that day. The call
will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary
Titus, Senior Vice President and CFO.

LIVE CALL: 866.831.6224 (U.S./Canada)
617.213.8853 (International)
17214706 (Participant code)
REPLAY: 888.286.8010 (U.S./Canada)
617.801.6888 (International)
Passcode: 63433498

(Replay available from Wednesday, March 16, 2011 at 7:30 p.m. ET
until 11:59 p.m. ET on Wednesday, March 23, 2011)

The conference call will contain forward-looking statements. Interested
parties who wish to listen to the webcast should visit the Investor
Relations section of SciClone's website at www.sciclone.com. The
information provided on the teleconference is accurate only at the time
of the conference call, and SciClone will take no responsibility for
providing updated information except as required by law.

About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a
revenue-generating, China-centric, specialty pharmaceutical company with
a substantial international business and a product portfolio of novel
therapies for cancer and infectious diseases. The Company is focused on
continuing sales growth and executing a clinical development strategy
with prudently managed costs. ZADAXIN(R) (thymalfasin) is approved in
over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C
(HCV), certain cancers, and as a vaccine adjuvant. SciClone is evaluating
SCV-07 in a phase 2b trial to modify the course of oral mucositis in
patients with head and neck cancer. The Company also has exclusive
commercialization and distribution rights in China to a novel treatment
for advanced liver cancer, DC Bead(R), which is already approved in
approximately 40 countries worldwide, including the U.S. and several
countries in Europe. DC Bead is currently under review by regulatory
agencies in China. Additionally, SciClone owns exclusive
commercialization and distribution rights to the anti-nausea drug
ondansetron RapidFilm(R) in China, including Hong Kong and Macau, and
Vietnam. The Company intends to seek regulatory approval for the product,
commonly used to treat and prevent nausea and vomiting caused by
chemotherapy, radiotherapy, and surgery, in these markets. For additional
information, please visit www.sciclone.com

DC Bead is a registered trademark of Biocompatibles UK Limited.

RapidFilm is a registered trademark of Labtec Gesellschaft fuer
technologische Forschung und Entwicklung mbH.

Corporate Contact:
Ana Kapor
SciClone Pharmaceuticals, Inc.
650.350.3825
akapor@sciclone.com

Copyright 2011, Market Wire, All rights reserved.

-0-